Prostate Cancer | Specialty

Men With Intermediate or High-Risk Prostate Cancer See Survival Benefit From Increased Radiation Therapy

August 4th 2015

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Novel Radium-223 Combinations on the Horizon in Bone-Metastatic CRPC

July 29th 2015

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.

Dr. Edith Mitchell on Cancer Disparities Among African American Patients

July 29th 2015

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Concurrent Statin Use in ADT Patients Reduced All Cause, Prostate Cancer-Specific Deaths

July 29th 2015

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Dr. O'Sullivan on Radium-223 With Enzalutamide and Abiraterone in mCRPC

July 28th 2015

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Improved Survival Data Seen With Abiraterone as COUGAR Trial Concludes

July 27th 2015

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

Dr. Meng on MRI-US Fusion Targeted Biopsy for High-Grade Prostate Cancer

July 24th 2015

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Dr. Karsh on the TERRAIN Trial for Prostate Cancer

July 13th 2015

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Sequencing Strategies for Radium-223: Still in Its Nascence?

July 6th 2015

Neal Shore, MD, recently visited the OncLive News Network studios to discuss his role in LUGPA and provide his clinical insights about skeletal complications and the sequencing of radium-223.

Radium-223 Focus of Several Ongoing Combination Studies in mCRPC

June 30th 2015

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.

A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

June 28th 2015

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Fluoride PET/CT Scan Could Guide Treatment Selection in Bone Metastatic CRPC

June 26th 2015

Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.

Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

June 23rd 2015

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer Prevention

June 18th 2015

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Performance Status in Progressive mCRPC

June 11th 2015

Case Study: Symptomatic, Progressing mCRPC

June 11th 2015

Sequential and Combined Therapies in mCRPC

June 11th 2015

Case Study: Newly Diagnosed Metastatic Prostate Cancer

June 11th 2015

Importance of Detecting Early Metastasis in CRPC

June 11th 2015

Case Study: Newly Diagnosed High-Risk Prostate Cancer

June 11th 2015